Wu, Mike C. L. https://orcid.org/0000-0002-4039-4409
Italiano, Ethan https://orcid.org/0009-0006-8170-7105
Jarvis-Child, Rocko https://orcid.org/0009-0002-2095-5157
Alwis, Imala
Smythe, Rhyll https://orcid.org/0009-0002-3652-6197
Albornoz, Eduardo A. https://orcid.org/0000-0002-9976-6350
Noonan, Jonathan https://orcid.org/0000-0001-9173-0903
Portelli, Marie
Baptista, Marissa
Maclean, Jessica
Noori, Pashtana
Yang, Jinglu
Lee, John D.
McFadyen, James D.
Sharland, Alexandra F. https://orcid.org/0000-0003-1579-5398
Woodruff, Trent M. https://orcid.org/0000-0003-1382-911X
Samson, Andre L. https://orcid.org/0000-0002-0637-2716
Rapkiewicz, Amy
Barrett, Tessa J.
Pham, Alan
Schoenwaelder, Simone M. https://orcid.org/0000-0003-0465-5840
Yuan, Yuping
Jackson, Shaun P. https://orcid.org/0000-0002-4750-1991
Article History
Received: 16 January 2024
Accepted: 28 April 2025
First Online: 4 June 2025
Competing interests
: A.L.S. has contributed to the development of necroptosis pathway inhibitors in collaboration with Anaxis Pharma. The other authors declare no competing interests.